+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity



β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity



Molecular Medicine Reports 7(1): 259-265



Common functional polymorphisms in β-adrenergic receptor (βAR) genes have been associated with heart failure (HF) phenotypes and pharmacogenetic interactions with βAR blockers. This study evaluated the association between βAR polymorphisms and carvedilol drug response and prognosis in patients with HF. In this prospective cohort controlled study, 326 volunteers were enrolled [146 HF patients (ejection fraction (EF)<50% by Simpson) and 180 healthy controls]. Drug response was evaluated by echocardiography and outcomes were mortality and hospitalization. DNA was extracted from peripheral blood leukocytes, fragments were amplified by the polymerase reaction and genotyped by restriction fragment length polymorphism (RFLP) for Ser49Gly and Arg389Gly βAR-1 polymorphisms and Gln27Glu and Arg16Gly βAR-2 polymorphisms. The study population was in Hardy‑Weinberg equilibrium. The survival rate was adjusted using the Kaplan-Meier method. HF patients showed the following characteristics: EF 35±9%, 69.9% male, age 59±13 years, 50.7% self-identified as black, 46% had ischemic etiology. The mean follow-up of 23 months showed 18 mortalities and 46 hospitalizations. The genotypes Glu27Glu (24.7 vs. 6.1%, p=0.0004) and Arg16Arg (72.6 vs. 22.8, p<0.0001) of βAR2 polymorphisms and Gly49Gly (33.6 vs. 4.3%, p<0.0001) of the βAR1 polymorphism were higher in HF patients compared with controls. Patients with hospital admission showed a significantly higher Gly389 allelic frequency (54.9 vs. 42.1%, p=0.039), and the trend prevailed among patients who succumbed to the disease (61.1%, p=0.047). Black patients with the Ser49Ser genotype showed a reduced survival compared with the Gly49Gly or Ser49Gly genotypes (p=0.028). There was no association between improved LVEF >20% and βAR polymorphisms. HF patients with β-blocker therapy and the Gly389 allele have reduced event-free survival compared to those carrying the Arg389 allele. Additionally, systolic HF outpatients undergoing β-blocker therapy, self‑identified as black and homozygous for Ser49Ser may have reduced event-free survival, while Glu27Glu, Arg16Arg and Gly49Gly genotypes may be associated with risk for HF.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056998408

Download citation: RISBibTeXText

PMID: 23064657

DOI: 10.3892/mmr.2012.1120


Related references

β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis. Plos One 7(7): E37659, 2013

Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. American Journal of Cardiology 102(6): 726-732, 2008

Consideration of beta-1 adrenergic receptor polymorphisms along with traditional risk factors as predictors of prognosis in patients with heart failure. Clinical Pharmacology & Therapeutics 75(2): P55, February, 2004

Association study of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene with susceptibility and prognosis of heart failure. Gene 510(1): 7-13, 2012

Impact of beta-2 Thr164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients. Brazilian Journal of Medical and Biological Research 43(6): 565-571, 2011

Merck cardiovascular research fellowship Effect of beta-adrenergic receptor polymorphisms on the response to metoprolol CR/XL in heart failure. Pharmacotherapy 22(10): 1389, October, 2002

Relationship between beta-1 adrenergic receptor polymorphisms and the response to beta-blockers in patients with heart failure. Circulation 104(17 Supplement): II 661-II 662, October 23, 2001

Adrenergic-receptor polymorphisms and heart failure. New England Journal of Medicine 347(15): 1196-1199, 2002

Beta2-Adrenergic receptor polymorphisms are not associated with heart failure. FASEB Journal 16(4): A587, March 20, 2002

The role of adrenergic receptor polymorphisms in heart failure. Brazilian Journal of Medical and Biological Research 39(10): 1281-1290, 2006

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics 15(3): 137-142, 2005

Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. Heart Failure Clinics 6(1): 27-33, 2010

Adrenergic receptor polymorphisms in heart failure: what can genetics explain?. Arquivos Brasileiros de Cardiologia 94(6): 841-849, 2011

Polymorphisms of matrix metalloproteinases in systolic heart failure: role on disease susceptibility, phenotypic characteristics, and prognosis. Journal of Cardiac Failure 17(2): 115-121, 2011

Beta1 and beta2-Adrenergic receptor gene polymorphisms are not associated with heart failure. FASEB Journal 17(4-5): Abstract No 401 1, March, 2003